{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:43:51Z","timestamp":1793241831474,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Identifying risk factors in papillary thyroid carcinoma (PTC) that warrant more aggressive treatment is paramount. Importantly, the prevalence and clinical significance of\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E mutation in PTC remain debatable. This study aims to determine the association of\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E with demographic and clinicopathologic characteristics, including recurrence. Single institution data from consecutive PTC patients with\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E immunohistochemistry and\/or molecular testing was collected between 2018 and 2022, including BRAF status, morphologic subtype, TN category, tumor size, nodal disease burden, tumor multifocality, extrathyroidal extension, treatment, follow-up time, loco-regional and distant recurrence, and mortality. This study included 301 patients, 30% male. The majority had\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E mutation (78.7%), and\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E was associated with morphologic subtype (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), with 88% of classic subtype PTCs, 38% of PTCs with extensive follicular growth, and 100% of tall cell subtype expressing\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E.\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E was not associated with tumor size (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.696) or nodal disease burden (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.962). On multivariate analysis using Cox proportional hazard model, large volume nodal disease burden (HR 3.37, 95%CI 1.49\u20137.64,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) and male gender (HR 2.29, 95%CI 1.23\u20134.26,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) were significantly associated with recurrence.\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E (HR 0.71, 95% CI 0.31\u20131.65,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.4) was not significantly associated with recurrence. In conclusion, presence of\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E in the absence of high risk histologic features does not have an impact on PTC recurrence, and thus, its utility in risk stratification is questionable in the setting of other clinicopathologic risk factors.\n                  <\/jats:p>","DOI":"10.1007\/s12022-025-09859-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T03:22:17Z","timestamp":1744773737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma"],"prefix":"10.1007","volume":"36","author":[{"given":"Alexandria","family":"Brumfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Abou","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Nordgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier M.","family":"Keutgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Applewhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Angelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-2746","authenticated-orcid":false,"given":"Nicole A.","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"9859_CR1","unstructured":"Thyroid cancer - papillary carcinoma: MedlinePlus Medical Encyclopedia. https:\/\/medlineplus.gov\/ency\/article\/000331.htm. Accessed 10 Jul 2023"},{"key":"9859_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676\u2013690. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"key":"9859_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4158\/EP10407.RA","volume":"17","author":"GH Daniels","year":"2011","unstructured":"Daniels GH (2011) What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 17:768\u2013787. https:\/\/doi.org\/10.4158\/EP10407.RA","journal-title":"Endocr Pract"},{"key":"9859_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.critrevonc.2013.12.007","volume":"90","author":"O Omur","year":"2014","unstructured":"Omur O, Baran Y (2014) An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol 90:233\u2013252. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"9859_CR5","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.3390\/cancers12113146","volume":"12","author":"A Rangel-Pozzo","year":"2020","unstructured":"Rangel-Pozzo A, Sisdelli L, Cordioli MIV, Vaisman F, Caria P, Mai S, Cerutti JM (2020) Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. Cancers 12:3146. https:\/\/doi.org\/10.3390\/cancers12113146","journal-title":"Cancers"},{"key":"9859_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MD.0b013e31826a9c71","volume":"91","author":"RP Tufano","year":"2012","unstructured":"Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M (2012) BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis. Medicine 91:274. https:\/\/doi.org\/10.1097\/MD.0b013e31826a9c71","journal-title":"Medicine"},{"key":"9859_CR7","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1210\/jc.2012-2104","volume":"97","author":"C Li","year":"2012","unstructured":"Li C, Lee KC, Schneider EB, Zeiger MA (2012) BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism 97:4559\u20134570. https:\/\/doi.org\/10.1210\/jc.2012-2104","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"9859_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/eci.12577","volume":"46","author":"Z Wang","year":"2016","unstructured":"Wang Z, Chen J-Q, Liu J-L, Qin X-G (2016) Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis. European Journal of Clinical Investigation 46:146\u2013157. https:\/\/doi.org\/10.1111\/eci.12577","journal-title":"European Journal of Clinical Investigation"},{"key":"9859_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s11596-018-1945-7","volume":"38","author":"J Song","year":"2018","unstructured":"Song J, Sun S, Dong F, Huang T, Wu B, Zhou J (2018) Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis. CURR MED SCI 38:785\u2013797. https:\/\/doi.org\/10.1007\/s11596-018-1945-7","journal-title":"CURR MED SCI"},{"key":"9859_CR10","doi-asserted-by":"publisher","first-page":"9959649","DOI":"10.1155\/2022\/9959649","volume":"2022","author":"X Wei","year":"2022","unstructured":"Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J (2022) Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma. Biomed Res Int 2022:9959649. https:\/\/doi.org\/10.1155\/2022\/9959649","journal-title":"Biomed Res Int"},{"key":"9859_CR11","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3390\/cancers12082056","volume":"12","author":"X Li","year":"2020","unstructured":"Li X, Kwon H (2020) The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis. Cancers (Basel) 12:2056. https:\/\/doi.org\/10.3390\/cancers12082056","journal-title":"Cancers (Basel)"},{"key":"9859_CR12","unstructured":"DeLellis R, Lloyd R, Heitz P, Eng C Pathology and Genetics of Tumours of Endocrine Organs, 3rd ed. International Agency for Research on Cancer, Lyon, France"},{"key":"9859_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/jc.2015-2917","volume":"101","author":"X Shi","year":"2016","unstructured":"Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Sim\u00f5es M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O\u2019Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M (2016) Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab 101:264\u2013274. https:\/\/doi.org\/10.1210\/jc.2015-2917","journal-title":"J Clin Endocrinol Metab"},{"key":"9859_CR14","unstructured":"Lloyd R, Osamura R, Kl\u00f6ppel G, Rosai J WHO Classification of Tumours of Endocrine Organs, 4th ed. International Agency for Research on Cancer, Lyon, France"},{"key":"9859_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/PAP.0000000000000184","volume":"25","author":"MC Nath","year":"2018","unstructured":"Nath MC, Erickson LA (2018) Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid. Adv Anat Pathol 25:172\u2013179. https:\/\/doi.org\/10.1097\/PAP.0000000000000184","journal-title":"Adv Anat Pathol"},{"key":"9859_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/ERC-15-0057","volume":"22","author":"MS Dettmer","year":"2015","unstructured":"Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A (2015) Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 22:419\u2013429. https:\/\/doi.org\/10.1530\/ERC-15-0057","journal-title":"Endocr Relat Cancer"},{"key":"9859_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1089\/thy.2013.0503","volume":"24","author":"I Ganly","year":"2014","unstructured":"Ganly I, Ibrahimpasic T, Rivera M, Nixon I, Palmer F, Patel SG, Tuttle RM, Shah JP, Ghossein R (2014) Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 24:662\u2013670. https:\/\/doi.org\/10.1089\/thy.2013.0503","journal-title":"Thyroid"},{"key":"9859_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/modpathol.2017.130","volume":"31","author":"RR Seethala","year":"2018","unstructured":"Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, LiVolsi VA, Nikiforov YE, Tallini G, Thompson LD (2018) Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Modern Pathology 31:39\u201355. https:\/\/doi.org\/10.1038\/modpathol.2017.130","journal-title":"Modern Pathology"},{"key":"9859_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.5858\/arpa.2017-0118-OA","volume":"142","author":"DN Johnson","year":"2018","unstructured":"Johnson DN, Furtado LV, Long BC, Zhen CJ, Wurst M, Mujacic I, Kadri S, Segal JP, Antic T, Cipriani NA (2018) Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth. Arch Pathol Lab Med 142:838\u2013850. https:\/\/doi.org\/10.5858\/arpa.2017-0118-OA","journal-title":"Arch Pathol Lab Med"},{"key":"9859_CR20","unstructured":"(2022) WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine tumours, 5th ed. International Agency for Research on Cancer, Lyon, France"},{"key":"9859_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/thy.2014.0502","volume":"25","author":"RL Ferris","year":"2015","unstructured":"Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE (2015) American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. Thyroid 25:760\u2013768. https:\/\/doi.org\/10.1089\/thy.2014.0502","journal-title":"Thyroid"},{"key":"9859_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"9859_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0002-9343(87)90758-3","volume":"83","author":"WJ Simpson","year":"1987","unstructured":"Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T (1987) Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am J Med 83:479\u2013488. https:\/\/doi.org\/10.1016\/0002-9343(87)90758-3","journal-title":"Am J Med"},{"key":"9859_CR24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/1097-0142(19910715)68:2<324::aid-cncr2820680220>3.0.co;2-s","volume":"68","author":"AM Schindler","year":"1991","unstructured":"Schindler AM, van Melle G, Evequoz B, Scazziga B (1991) Prognostic factors in papillary carcinoma of the thyroid. Cancer 68:324\u2013330. https:\/\/doi.org\/10.1002\/1097-0142(19910715)68:2<324::aid-cncr2820680220>3.0.co;2-s","journal-title":"Cancer"},{"key":"9859_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","volume":"97","author":"EL Mazzaferri","year":"1994","unstructured":"Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418\u2013428. https:\/\/doi.org\/10.1016\/0002-9343(94)90321-2","journal-title":"Am J Med"},{"key":"9859_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12893-022-01635-7","volume":"22","author":"L Zhan","year":"2022","unstructured":"Zhan L, Feng H, Yu X, Li L, Song J, Tu Y, Yuan J, Chen C, Sun S (2022) Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma. BMC Surg 22:235. https:\/\/doi.org\/10.1186\/s12893-022-01635-7","journal-title":"BMC Surg"},{"key":"9859_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1245\/s10434-014-3900-6","volume":"22","author":"CW Lee","year":"2015","unstructured":"Lee CW, Roh J-L, Gong G, Cho K-J, Choi S-H, Nam SY, Kim SY (2015) Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck. Ann Surg Oncol 22:117\u2013124. https:\/\/doi.org\/10.1245\/s10434-014-3900-6","journal-title":"Ann Surg Oncol"},{"key":"9859_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12957-017-1141-4","volume":"15","author":"YR Hong","year":"2017","unstructured":"Hong YR, Lee SH, Lim DJ, Kim MH, Jung CK, Chae BJ, Song BJ, Bae JS (2017) The stratification of patient risk depending on the size and ratio of metastatic lymph nodes in papillary thyroid carcinoma. World J Surg Oncol 15:74. https:\/\/doi.org\/10.1186\/s12957-017-1141-4","journal-title":"World J Surg Oncol"},{"key":"9859_CR29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s12105-020-01166-8","volume":"14","author":"KG Parker","year":"2020","unstructured":"Parker KG, White MG, Cipriani NA (2020) Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. Head Neck Pathol 14:1067\u20131079. https:\/\/doi.org\/10.1007\/s12105-020-01166-8","journal-title":"Head Neck Pathol"},{"key":"9859_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","volume":"19","author":"S Kadri","year":"2017","unstructured":"Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV, Segal JP (2017) Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn 19:43\u201356. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.07.012","journal-title":"J Mol Diagn"},{"key":"9859_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00428-021-03138-x","volume":"480","author":"A Tatjana","year":"2022","unstructured":"Tatjana A, Tjota MY, O\u2019Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang P (2022) EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch 480:487\u2013492. https:\/\/doi.org\/10.1007\/s00428-021-03138-x","journal-title":"Virchows Arch"},{"key":"9859_CR32","doi-asserted-by":"crossref","unstructured":"Kassambara A, Kosinski M, Biecek P (2016) survminer: Drawing Survival Curves using \u201cggplot2.\u201d 0.5.0","DOI":"10.32614\/CRAN.package.survminer"},{"key":"9859_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: Elegant Graphics for Data Analysis. Springer International Publishing, New York, NY"},{"key":"9859_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. Springer, New York, NY"},{"key":"9859_CR35","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373\u20136379. https:\/\/doi.org\/10.1210\/jc.2005-0987","journal-title":"J Clin Endocrinol Metab"},{"key":"9859_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"M Xing","year":"2007","unstructured":"Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742\u2013762. https:\/\/doi.org\/10.1210\/er.2007-0007","journal-title":"Endocr Rev"},{"key":"9859_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12020-023-03564-8","volume":"84","author":"J Cao","year":"2024","unstructured":"Cao J, Chen B, Zhu X, Sun Y, Li X, Zhang W, Wang X (2024) BRAF V600E mutation in papillary thyroid microcarcinoma: is it a predictor for the prognosis of patients with intermediate to high recurrence risk? Endocrine 84:160\u2013170. https:\/\/doi.org\/10.1007\/s12020-023-03564-8","journal-title":"Endocrine"},{"key":"9859_CR38","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1245\/s10434-012-2851-z","volume":"20","author":"X Zheng","year":"2013","unstructured":"Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M (2013) Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266\u20132273. https:\/\/doi.org\/10.1245\/s10434-012-2851-z","journal-title":"Ann Surg Oncol"},{"key":"9859_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12020-020-02380-8","volume":"71","author":"MT Sam\u00e0","year":"2021","unstructured":"Sam\u00e0 MT, Grosso E, Mele C, Laurora S, Monzeglio O, Marzullo P, Boldorini R, Aluffi Valletti P, Aimaretti G, Scatolini M, Pagano L (2021) Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma. Endocrine 71:149\u2013157. https:\/\/doi.org\/10.1007\/s12020-020-02380-8","journal-title":"Endocrine"},{"key":"9859_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1001\/jamaoto.2013.4501","volume":"139","author":"C Gouveia","year":"2013","unstructured":"Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA (2013) Lack of Association of BRAF Mutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma: The University of California, San Francisco, Experience. JAMA Otolaryngology\u2013Head & Neck Surgery 139:1164\u20131170. https:\/\/doi.org\/10.1001\/jamaoto.2013.4501","journal-title":"JAMA Otolaryngology-Head & Neck Surgery"},{"key":"9859_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.k08e-208","volume":"56","author":"Y Ito","year":"2009","unstructured":"Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89\u201397. https:\/\/doi.org\/10.1507\/endocrj.k08e-208","journal-title":"Endocr J"},{"key":"9859_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cam4.417","volume":"4","author":"LE Henke","year":"2015","unstructured":"Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, El-Mofty S, Moley JF, Nussenbaum B, Haughey BH, Baranski TJ, Schwarz JK, Grigsby PW (2015) BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. Cancer Med 4:791\u2013799. https:\/\/doi.org\/10.1002\/cam4.417","journal-title":"Cancer Med"},{"key":"9859_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12020-013-0029-5","volume":"45","author":"D Barbaro","year":"2014","unstructured":"Barbaro D, Incensati RM, Materazzi G, Boni G, Grosso M, Panicucci E, Lapi P, Pasquini C, Miccoli P (2014) The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 45:462\u2013468. https:\/\/doi.org\/10.1007\/s12020-013-0029-5","journal-title":"Endocrine"},{"key":"9859_CR44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2012.08.019","volume":"152","author":"KC Lee","year":"2012","unstructured":"Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA (2012) Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152:977\u2013983. https:\/\/doi.org\/10.1016\/j.surg.2012.08.019","journal-title":"Surgery"},{"key":"9859_CR45","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1210\/jc.2013-1584","volume":"98","author":"C Li","year":"2013","unstructured":"Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA (2013) Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab 98:3702\u20133712. https:\/\/doi.org\/10.1210\/jc.2013-1584","journal-title":"J Clin Endocrinol Metab"},{"key":"9859_CR46","doi-asserted-by":"publisher","unstructured":"Hang J-F, Chen J-Y, Kuo P-C, Lai H-F, Lee T-L, Tai S-K, Kuo C-S, Chen H-S, Li W-S, Li C-F (2023) A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. Modern Pathology 36:. https:\/\/doi.org\/10.1016\/j.modpat.2023.100242","DOI":"10.1016\/j.modpat.2023.100242"},{"key":"9859_CR47","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O\u2019Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493\u20131501. https:\/\/doi.org\/10.1001\/jama.2013.3190","journal-title":"JAMA"},{"key":"9859_CR48","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/cncr.26500","volume":"118","author":"TH Kim","year":"2012","unstructured":"Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park DJ (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764\u20131773. https:\/\/doi.org\/10.1002\/cncr.26500","journal-title":"Cancer"},{"key":"9859_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.2018.0775","volume":"30","author":"A Zahedi","year":"2020","unstructured":"Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE, Pathak KA, Bureau Y, Rachinsky I, Badreddine M, De Brabandere S, Fong H, Maniakas A, Van Uum S (2020) Risk for Thyroid Cancer Recurrence Is Higher in Men Than in Women Independent of Disease Stage at Presentation. Thyroid 30:871\u2013877. https:\/\/doi.org\/10.1089\/thy.2018.0775","journal-title":"Thyroid"},{"key":"9859_CR50","first-page":"5393","volume":"7","author":"K Guo","year":"2014","unstructured":"Guo K, Wang Z (2014) Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol 7:5393\u20135403","journal-title":"Int J Clin Exp Pathol"},{"key":"9859_CR51","doi-asserted-by":"publisher","first-page":"777345","DOI":"10.3389\/fendo.2022.777345","volume":"13","author":"AK Siraj","year":"2022","unstructured":"Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Siraj N, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS (2022) Male Sex Is an Independent Predictor of Recurrence-Free Survival in Middle Eastern Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 13:777345. https:\/\/doi.org\/10.3389\/fendo.2022.777345","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9859_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yexmp.2018.07.006","volume":"105","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang L, Wang J, Zhao H, Wu J, Liu S, Zhang L, Li Y, Xing X (2018) Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma. Experimental and Molecular Pathology 105:153\u2013159. https:\/\/doi.org\/10.1016\/j.yexmp.2018.07.006","journal-title":"Experimental and Molecular Pathology"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09859-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:25:44Z","timestamp":1767860744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9859"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09859-y","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"9 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate was waived by the Institutional Board Review committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Humans"}},{"value":"Nicole Cipriani is an editorial board member of Endocrine Pathology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}